Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr class="thead"><td align="left"> </td><td align="center" colspan="4">NET protein intensity grading</td></tr><tr class="thead"><td align="left"> </td><td align="center">0</td><td align="center">1+</td><td align="center">2+</td><td align="center">3+</td></tr><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr><td align="left">MIBG Nonavid</td><td align="center">3</td><td align="center">4</td><td align="center">0</td><td align="center">1</td></tr><tr><td align="left">MIBG Avid</td><td align="center">2</td><td align="center">3</td><td align="center">7</td><td align="center">3</td></tr><tr class="table-tr"><td colspan="5"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

NET protein expression intensity score according to MIBG avidity in 23 patients with neuroblastoma and centrally reviewed MIBG scans.

International Journal of Molecular Imaging

tab2

Table 2

Table 2: Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group 

Table 2 | Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group 